TELA Bio Inc. (TELA) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, TELA scores 39 out of 100 (letter grade D-), labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 9 / 20. The rating cites ROIC of -35% and FCF yield of 0%, indicating the business is not currently generating returns on capital or free cash flow to shareholders. For a prospective investor, the upside case depends on a future inflection to positive cash generation that the source data does not yet show.
• Whale 13F Flow: 8 / 20. The rating reflects institutional accumulation and options positioning. The source data contains no holder records (see Analyst View section), so the basis for this pillar cannot be independently verified here.
• Insider Conviction: 5 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar after the cash engine's weakness, and a low score signals limited insider-level confidence in the near term.
• Macro Regime Fit: 8 / 20. The rating cites beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive cushion in a downturn.
• Forensic Balance Sheet: 9 / 20. The rating cites Altman Z-Score of 2.5, Piotroski F-Score of 4/9, and Debt/Equity of 8.5. These collectively point to financial fragility: a Piotroski score of 4 out of 9 indicates weak fundamental health signals, and the high leverage ratio increases dependence on continued financing.

Taken together, the rating frames TELA as a high-risk speculative situation. The upside argument rests on a turnaround in operating economics that has not yet appeared in reported results; the downside risk is balance-sheet pressure and continued cash burn. This is an educational reading of the scored inputs, not a recommendation.

TELA Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the company profile, its market capitalization is $0.0B. Per the news wire, the company has received FDA 510(k) clearance for its Liora Monofilament Scaffold, described as a soft-tissue reinforcement product, which suggests its product line centers on surgical implant-type devices. Revenue figures are reported in the financials section. Customer and channel detail is not available in source data.

Revenue grew from $58.5M (FY 2023) to $69.3M (FY 2024) and $80.3M (FY 2025), while operating losses remained in the $-33.8M to $-44.1M range across all three periods. Per the market data, gross margin is 67.7%, operating margin -42%, and net margin -48.3%, with ROIC of -35%. The forensic metrics cited in the RQD rating (Altman Z-Score 2.5; Piotroski F-Score 4/9; Debt/Equity 8.5) indicate a stressed but not distressed profile. Cash declined from $52.7M to $50.8M while debt rose from $41.1M to $55.7M between FY 2024 and FY 2025.

Per the news wire, the most prominent catalysts are:

• FDA 510(k) clearance for the Liora Monofilament Scaffold, reported across multiple outlets (Yahoo Finance, Quiver Quantitative, Stock Titan). This is the principal product-regulatory catalyst in the feed and is directly relevant to the company's stated soft-tissue reconstruction focus.
• Director equity compensation: a Form 4 filing for director Joseph H. Capper (dated 15 October) and a Stock Titan report describing stock replacing cash pay in a 19,801-share award. This is routine governance activity and carries limited signal weight.
• Upcoming earnings: a headline announcing the Third Quarter 2026 financial results release date.

Risk watch items: the news feed contains no revenue guidance, reimbursement detail, or commercial-adoption metrics for the cleared product, so the commercial impact of the clearance cannot be quantified from source data. The Butterfly Supply-Chain Graph reports no proprietary signals (see next section). All news items carry a YELLOW light designation in the source feed.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector-correlation links are therefore not available in source data. A prospective investor should note that the absence of mapped dependencies is itself a gap: the company's reliance on specific component suppliers, surgical-channel customers, or reimbursement pathways cannot be assessed from these sources. The only sector-level context available is the Health Care / Medical-Dental Instruments classification and the beta of 1.0.

• What commercial revenue, if any, is expected from the Liora Monofilament Scaffold following FDA 510(k) clearance, and on what timeline?
• What is the company's cash runway given FY 2025 FCF of $-28.7M against cash of $50.8M, and how is the rise in debt to $55.7M being financed?
• What are the Q3 2026 results when released, and do they show improvement in operating margin from the -42% level?
• Who are the institutional holders and what is the 13F accumulation trend that the RQD rating's whale-flow pillar references?
• What are the company's principal upstream suppliers and downstream customers, given that the supply-chain graph is empty?